Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
ID | DOID:707 |
Name | B-cell lymphoma |
Definition | A non-Hodgkin lymphoma that has_material_basis_in B cells. |
Source | DiseaseOntology.org |
Alt Ids | |
Path | disease disease of cellular proliferation cancer organ system cancer hematologic cancer lymphoma non-Hodgkin lymphoma B-cell lymphoma |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT00881920 | Phase I | CAR.k.28 cells Cyclophosphamide + Fludarabine | Kappa-CD28 T Lymphocytes, Chronic Lymphocytic Leukemia, B-cell Lymphoma or Multiple Myeloma, CHARKALL (CHARKALL) | Recruiting | USA | 0 |
NCT01084252 | Phase Ib/II | Isatuximab Dexamethasone + Isatuximab | Phase 1/2 Dose Escalation and Efficacy Study of Anti-CD38 Monoclonal Antibody in Patients With Selected CD38+ Hematological Malignancies | Active, not recruiting | USA | 16 |
NCT01087294 | Phase I | Anti-CD19 CAR T cells | Administration of Anti-CD19-chimeric-antigen-receptor-transduced T Cells From the Original Transplant Donor to Patients With Recurrent or Persistent B-cell Malignancies After Allogeneic Stem Cell Transplantation | Recruiting | USA | 0 |
NCT01109069 | Phase II | Ibrutinib | Safety and Tolerability Study of PCI-32765 in B Cell Lymphoma and Chronic Lymphocytic Leukemia | Completed | USA | 0 |
NCT01193842 | Phase Ib/II | Vorinostat Cyclophosphamide + Doxorubicin + Etoposide + Methylprednisolone + Rituximab + Vincristine Sulfate | Vorinostat and Combination Chemotherapy With Rituximab in Treating Patients With HIV-Related Diffuse Large B-Cell Non-Hodgkin Lymphoma or Other Aggressive B-Cell Lymphomas | Active, not recruiting | USA | 0 |
NCT01307267 | Phase I | Rituximab + Utomilumab Utomilumab | A Study Of PF-05082566 As A Single Agent And In Combination With Rituximab | Completed | USA | 4 |
NCT01695941 | Phase I | Alisertib + Bortezomib + Rituximab | Alisertib, Bortezomib, and Rituximab in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma or B-cell Low Grade Non-Hodgkin Lymphoma | Active, not recruiting | USA | 0 |
NCT01742988 | Phase Ib/II | Bendamustine + CUDC-907 + Rituximab CUDC-907 + Rituximab CUDC-907 CUDC-907 + Venetoclax | Study to Assess the Safety, Tolerability and Pharmacokinetics of Fimepinostat (CUDC-907) in Patients With Lymphoma | Active, not recruiting | USA | 0 |
NCT01799889 | Phase II | Entospletinib | A Phase 2 of Entospletinib in Subjects With Relapsed or Refractory Hematologic Malignancies | Terminated | USA | CAN | 0 |
NCT01853631 | Phase I | Anti-CD19 CAR T cells Cyclophosphamide + Fludarabine | Activated T-Cells Expressing 2nd or 3rd Generation CD19-Specific CAR, Advanced B-Cell NHL, ALL, and CLL (SAGAN) (SAGAN) | Recruiting | USA | 0 |
NCT01859819 | Phase II | Cytarabine + Rituximab | Treatment for Advanced B-Cell Lymphoma | Unknown status | USA | 0 |
NCT01976585 | Phase Ib/II | CDX-301 + Poly ICLC | In Situ Vaccine for Low-Grade Lymphoma: Combination of Intratumoral Flt3L and Poly-ICLC With Low-Dose Radiotherapy | Recruiting | USA | 0 |
NCT02006485 | Phase I | Ublituximab + Umbralisib Ibrutinib | Ublituximab in Combination With TGR-1202 in Patients With B-cell Malignancies | Completed | USA | 0 |
NCT02018861 | Phase I | Itacitinib Itacitinib + Parsaclisib Bendamustine Rituximab Carboplatin + Etoposide + Ifosfamide Parsaclisib | A Phase 1, Open-Label, Dose Escalation, Safety and Tolerability Study of INCB050465 Monotherapy and in Combination With INCB039110 in Subjects With Previously Treated B-Cell Malignancies | Active, not recruiting | USA | 0 |
NCT02106091 | Phase I | AFM11 | Safety Study to Assess AFM11 in Patients With Relapsed and/or Refractory CD19 Positive B-cell NHL | Terminated | USA | 3 |
NCT02153580 | Phase I | Etoposide Cyclophosphamide + Fludarabine Bendamustine | Cellular Immunotherapy Following Cyclophosphamide in Treating Patients With Recurrent Non-Hodgkin Lymphomas, Chronic Lymphocytic Leukemia or B-Cell Prolymphocytic Leukemia | Active, not recruiting | USA | 0 |
NCT02199184 | Phase II | Cyclophosphamide + Doxorubicin + Etoposide + Ofatumumab + Prednisone + Vincristine Sulfate Cyclophosphamide + Doxorubicin + Etoposide + Prednisone + Rituximab + Vincristine Sulfate | Dose Adjusted EPOCH Regimen in Combination With Ofatumumab or Rituximab in Treating Patients With Newly Diagnosed or Relapsed or Refractory Burkitt Lymphoma or Relapsed or Refractory Acute Lymphoblastic Leukemia | Recruiting | USA | 0 |
NCT02207062 | Phase I | Ibrutinib | Ibrutinib in Treating Patients With Relapsed or Refractory Transformed Indolent B-cell Non-Hodgkin Lymphoma | Active, not recruiting | USA | 0 |
NCT02213913 | Phase Ib/II | Lenalidomide Cyclophosphamide + Doxorubicin + Etoposide + Prednisone + Rituximab + Vincristine Sulfate | Lenalidomide and Combination Chemotherapy (DA-EPOCH-R) in Treating Patients With MYC-Associated B-Cell Lymphomas | Recruiting | USA | 0 |
NCT02253992 | Phase Ib/II | Nivolumab + Urelumab | Study of the Safety and Tolerability of Urelumab Administered in Combination With Nivolumab in Solid Tumors and B-cell Non-Hodgkins Lymphoma | Terminated | USA | 3 |
NCT02254772 | Phase Ib/II | Ipilimumab + SD-101 | TLR9 Agonist SD-101, Ipilimumab, and Radiation Therapy in Treating Patients With Low-Grade Recurrent B-cell Lymphoma | Completed | USA | 0 |
NCT02266147 | Phase Ib/II | SD-101 | Study of SD-101 in Combination With Localized Low-dose Radiation in Patients With Untreated Low-grade B-cell Lymphoma | Terminated | USA | 0 |
NCT02272686 | Phase II | Ibrutinib | Ibrutinib Post Stem Cell Transplantation (SCT) in Double-Hit B-Cell Lymphoma | Terminated | USA | 0 |
NCT02290951 | Phase I | Rituximab Odronextamab | Study to Investigate the Safety and Tolerability of REGN1979 in Patients With CD20+ B-Cell Malignancies | Active, not recruiting | USA | 1 |
NCT02315612 | Phase I | Anti-CD22 CAR T cells | Anti-CD22 Chimeric Receptor T Cells in Pediatric and Young Adults With Recurrent or Refractory CD22-expressing B Cell Malignancies | Recruiting | USA | 0 |
NCT02328014 | Phase Ib/II | ACP-319 Acalabrutinib | ACP-196 in Combination With ACP-319, for Treatment of B-Cell Malignancies | Active, not recruiting | USA | 0 |
NCT02343120 | Phase I | Zanubrutinib | Study of the Safety and Pharmacokinetics of BGB-3111 in Subjects With B-Cell Lymphoid Malignancies | Active, not recruiting | USA | 5 |
NCT02395601 | Phase I | CPI-1205 | A Study Evaluating CPI-1205 in Patients With B-Cell Lymphomas | Completed | USA | 0 |
NCT02436707 | Phase II | Ibrutinib Cisplatin + Dexamethasone + Gemcitabine + Rituximab | Novel Combination Therapy in the Treatment of Relapsed and Refractory Aggressive B-Cell Lymphoma | Recruiting | CAN | 0 |
NCT02443077 | Phase III | Cyclophosphamide Carmustine + Cytarabine + Etoposide + Melphalan Ibrutinib | Ibrutinib Before and After Stem Cell Transplant in Treating Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma | Recruiting | USA | 1 |
NCT02457598 | Phase I | Entospletinib + Tirabrutinib Tirabrutinib Idelalisib + Obinutuzumab + Tirabrutinib Entospletinib + Obinutuzumab + Tirabrutinib Idelalisib + Tirabrutinib | Dose Escalation and Dose Expansion Study of Tirabrutinib in Combination With Other Targeted Anti-cancer Therapies in Adults With B-cell Malignancies | Active, not recruiting | USA | 2 |
NCT02500407 | Phase I | Atezolizumab + BTCT4465A | A Safety and Pharmacokinetic Study of BTCT4465A (Mosunetuzumab) as a Single Agent and Combined With Atezolizumab in Non-Hodgkin's Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL) | Recruiting | USA | CAN | 6 |
NCT02543879 | Phase I | FT-1101 Azacitidine + FT-1101 | Study of a Novel BET Inhibitor FT-1101 in Patients With Relapsed or Refractory Hematologic Malignancies | Completed | USA | 0 |
NCT02569476 | Phase I | Obinutuzumab + Zanubrutinib | BGB 3111 in Combination With Obinutuzumab in Subjects With B-Cell Lymphoid Malignancies | Active, not recruiting | USA | 2 |
NCT02600897 | Phase Ib/II | Lenalidomide + Rituximab Lenalidomide + Obinutuzumab Lenalidomide + Polatuzumab vedotin-piiq + Rituximab Lenalidomide + Obinutuzumab + Polatuzumab vedotin-piiq | A Study of Obinutuzumab, Polatuzumab Vedotin, and Lenalidomide in Relapsed or Refractory Follicular Lymphoma (FL) and Rituximab in Combination With Polatuzumab Vedotin and Lenalidomide in Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL) | Active, not recruiting | USA | 2 |
NCT02611323 | Phase Ib/II | Polatuzumab vedotin-piiq + Rituximab + Venetoclax Obinutuzumab + Polatuzumab vedotin-piiq + Venetoclax | A Study of Obinutuzumab, Rituximab, Polatuzumab Vedotin, and Venetoclax in Relapsed or Refractory Follicular Lymphoma (FL) or Diffuse Large B-Cell Lymphoma (DLBCL) | Active, not recruiting | USA | 2 |
NCT02624986 | Phase Ib/II | Idasanutlin + Obinutuzumab | A Study of Obinutuzumab With Idasanutlin in Relapsed or Refractory Follicular Lymphoma (FL) or Diffuse Large B-Cell Lymphoma (DLBCL) | Terminated | USA | 4 |
NCT02628405 | Phase Ib/II | Carboplatin + Etoposide + Ifosfamide + Lenalidomide + Rituximab | R-ICE and Lenalidomide in Treating Patients With First-Relapse/Primary Refractory Diffuse Large B-Cell Lymphoma | Recruiting | USA | 0 |
NCT02631044 | Phase I | Lisocabtagene maraleucel | Study Evaluating the Safety and Pharmacokinetics of JCAR017 in B-cell Non-Hodgkin Lymphoma (TRANSCEND-NHL-001) | Recruiting | USA | 0 |
NCT02693535 | Phase II | Cobimetinib + Vemurafenib Regorafenib Ipilimumab + Nivolumab Palbociclib Afatinib Talazoparib Pembrolizumab Temsirolimus Pertuzumab + Trastuzumab Crizotinib Abemaciclib Sunitinib Olaparib | TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer | Recruiting | USA | 0 |
NCT02706405 | Phase I | Cyclophosphamide + Durvalumab + JCAR014 | JCAR014 and Durvalumab in Treating Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma | Recruiting | USA | 0 |
NCT02715843 | Expanded access | MT-3724 | Extended Treatment Access Study of MT-3724 for Subjects With Relapsed Non-Hodgkin's B-Cell Lymphoma | No longer available | USA | 0 |
NCT02733042 | Phase Ib/II | Rituximab Durvalumab + Lenalidomide + Rituximab Bendamustine + Durvalumab + Rituximab Durvalumab + Ibrutinib Durvalumab | A Study to Determine Dose, Safety, and Efficacy of Durvalumab as Monotherapy and in Combination Therapy in Subjects With Lymphoma or Chronic Lymphocytic Leukemia (FUSION NHL 001) | Active, not recruiting | USA | 6 |
NCT02846935 | Phase 0 | Decitabine + Tetrahydrouridine | p53/p16-Independent Epigenetic Therapy With Oral Decitabine/Tetrahydrouridine for Refractory/Relapsed Lymphoid Malignancies | Completed | USA | 0 |
NCT02875002 | Phase I | Belinostat + Volasertib | Study of Volasertib and Belinostat in Patients With Relapsed and Refractory Aggressive B-cell and T-cell Lymphomas | Withdrawn | USA | 0 |
NCT02898259 | Phase Ib/II | Ixazomib + Lenalidomide + Rituximab | Lenalidomide, Ixazomib, and Rituximab as Front-Line Therapy for High Risk Indolent B-Cell Lymphoma | Active, not recruiting | USA | 0 |
NCT02914938 | Phase I | ME-401 ME-401 + Rituximab | A Study of ME-401 in Subjects With CLL/SLL, FL, and B-cell Non Hodgkin's Lymphoma | Recruiting | USA | 1 |
NCT02924402 | Phase I | XmAb13676 | Study to Evaluate Safety and Tolerability of XmAb13676 in Patients With CD20-expressing Hematologic Malignancies | Recruiting | USA | 1 |
NCT02950220 | Phase I | Ibrutinib + Pembrolizumab | Pembrolizumab and Ibrutinib in Treating Patients With Relapsed or Refractory Non-Hodgkin Lymphoma | Completed | USA | 0 |
NCT02973113 | Phase I | EB-VST cells + Nivolumab | Nivolumab With Epstein Barr Virus Specific T Cells (EB-VSTS), Relapsed/Refractory EBV Positive Lymphoma (PREVALE) (PREVALE) | Active, not recruiting | USA | 0 |
NCT02992522 | Phase I | Lenalidomide + Obinutuzumab + Venetoclax | Obinutuzumab, Venetoclax, and Lenalidomide in Treating Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma | Recruiting | USA | 0 |
NCT02997761 | Phase II | Blinatumomab + Ibrutinib | Ibrutinib and Blinatumomab in Treating Patients With Relapsed or Refractory B Acute Lymphoblastic Leukemia | Recruiting | USA | 0 |
NCT03019640 | Phase II | Carmustine + Cytarabine + Etoposide + Filgrastim + Lenalidomide + Melphalan + Rituximab | Immunotherapy With Ex Vivo-Expanded Cord Blood-Derived NK Cells Combined With Rituximab High-Dose Chemotherapy and Autologous Stem Cell Transplant for B-Cell Non-Hodgkin's Lymphoma | Recruiting | USA | 0 |
NCT03028103 | Phase I | Fluconazole + Tazemetostat Omeprazole + Repaglinide + Tazemetostat | Open-Label, Multicenter, Two-Part, Phase 1 Study to Characterize Effects of a Moderate CYP3A Inhibitor on PK of Tazemetostat, the Effects of Tazemetostat on PK of CYP2C8 and CYP2C19 Substrates, and the Effect of Increased Gastric pH on PK of Tazemetostat in B-cell Lymphoma Subjects | Active, not recruiting | USA | 0 |
NCT03036904 | Phase I | Cyclophosphamide + Doxorubicin + Etoposide + Prednisone + Rituximab + Venetoclax + Vincristine Sulfate | Study of Venetoclax Plus DA-EPOCH-R for the Treatment of Aggressive B-Cell Lymphomas (V+DA-EPOCH-R) | Active, not recruiting | USA | 0 |
NCT03038672 | Phase II | Nivolumab + Varlilumab Nivolumab | Nivolumab With or Without Varlilumab in Treating Patients With Relapsed or Refractory Aggressive B-cell Lymphomas | Recruiting | USA | 0 |
NCT03085173 | Phase I | EGFRt/19-28z/4-1BBL CAR T cells | A Trial of "Armored" CAR T Cells Targeting CD19 For Patients With Relapsed CD19+ Hematologic Malignancies | Active, not recruiting | USA | 0 |
NCT03103971 | Phase I | Cyclophosphamide + Fludarabine + HuJCAR014 | huJCAR014 CAR-T Cells in Treating Adult Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma or Acute Lymphoblastic Leukemia | Recruiting | USA | 0 |
NCT03133221 | Phase II | Idelalisib | 1630GCC: Zydelig Maintenance in B-Cell Non-Hodgkin's Lymphoma After Autologous Stem Cell Transplantation | Active, not recruiting | USA | 0 |
NCT03153462 | Expanded access | axicabtagene ciloleucel + Cyclophosphamide + Fludarabine | Axicabtagene Ciloleucel Expanded Access Study | Approved for marketing | USA | 0 |
NCT03217253 | Phase I | Tazemetostat | Tazemetostat in Treating Patients With Metastatic or Unresectable Solid Tumors or B-Cell Lymphomas With Liver Dysfunction | Withdrawn | USA | 0 |
NCT03223610 | Phase I | Ibrutinib + Lenalidomide + Obinutuzumab + Prednisone + Venetoclax | Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid (ViPOR) in Relapsed/Refractory B-cell Lymphoma | Recruiting | USA | 0 |
NCT03263026 | Phase III | Cyclophosphamide + Doxorubicin + Prednisone + Rituximab + Vincristine Sulfate Enzastaurin | Study to Assess Enzastaurin + R-CHOP in Subjects With DLBCL With the Genomic Biomarker DGM1 | Active, not recruiting | USA | 1 |
NCT03274492 | Phase III | Polatuzumab vedotin-piiq Cyclophosphamide + Doxorubicin + Prednisone + Rituximab Cyclophosphamide + Doxorubicin + Prednisone + Rituximab + Vincristine Sulfate | A Study Comparing the Efficacy and Safety of Polatuzumab Vedotin With Rituximab-Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab-Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Diffuse Large B-Cell Lymphoma | Active, not recruiting | USA | CAN | 22 |
NCT03277729 | Phase Ib/II | CD20 CAR T-cells + Cyclophosphamide + Fludarabine | A Phase I/II Study to Evaluate the Safety of Cellular Immunotherapy Using Autologous T Cells Engineered to Express a CD20-Specific Chimeric Antigen Receptor for Patients With Relapsed or Refractory B Cell Non-Hodgkin Lymphomas | Recruiting | USA | 0 |
NCT03287817 | Phase Ib/II | Pembrolizumab Cyclophosphamide + Fludarabine CD19/CD22 CAR T cells | CD19/22 CAR T Cells (AUTO3) for the Treatment of Diffuse Large B Cell Lymphoma (ALEXANDER) | Recruiting | USA | 1 |
NCT03310619 | Phase Ib/II | Durvalumab + Lisocabtagene maraleucel | A Safety and Efficacy Trial of JCAR017 Combinations in Subjects With Relapsed/Refractory B-cell Malignancies (PLATFORM) | Recruiting | USA | 0 |
NCT03328078 | Phase I | CA-4948 | A Study of CA-4948 in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma | Recruiting | USA | 0 |
NCT03410901 | Phase I | BMS-986178 + SD-101 | TLR9 Agonist SD-101, Anti-OX40 Antibody BMS 986178, and Radiation Therapy in Treating Patients With Low-Grade B-Cell Non-Hodgkin Lymphomas | Recruiting | USA | 0 |
NCT03424603 | Phase I | STRO-001 | Study of STRO-001, an Anti-CD74 Antibody Drug Conjugate, in Patients With Advanced B-Cell Malignancies | Recruiting | USA | 0 |
NCT03483103 | Phase II | Lisocabtagene maraleucel | Lisocabtagene Maraleucel (JCAR017) as Second-Line Therapy (TRANSCEND-PILOT-017006) | Active, not recruiting | USA | 0 |
NCT03488251 | Phase II | Gemcitabine + MT-3724 + Oxaliplatin | PK,PD, Safety and Tolerability of Multiple Dose Regimens of MT-3724 With Gemcitabine and Oxaliplatin for the Treatment of Patients With Relapsed/Refractory Diffuse Large B Cell Non-Hodgkin's Lymphoma | Active, not recruiting | USA | 0 |
NCT03570892 | Phase III | Lenalidomide Ibrutinib Carboplatin + Etoposide + Ifosfamide + Rituximab Carmustine + Cytarabine + Etoposide + Melphalan Cisplatin + Dexamethasone + Gemcitabine + Rituximab Cyclophosphamide + Fludarabine + Tisagenlecleucel Cisplatin + Cytarabine + Dexamethasone + Rituximab Gemcitabine + Oxaliplatin + Rituximab Bendamustine + Fludarabine + Tisagenlecleucel | Tisagenlecleucel in Adult Patients With Aggressive B-cell Non-Hodgkin Lymphoma (BELINDA) | Recruiting | USA | 17 |
NCT03573310 | Phase I | JNJ-64619178 | A Study of JNJ-64619178, an Inhibitor of PRMT5 in Participants With Advanced Solid Tumors, NHL, and Lower Risk MDS | Recruiting | USA | CAN | 3 |
NCT03579927 | Phase Ib/II | Filgrastim iC9-CAR.19-IL15-Transduced CB-NK Carmustine + Cytarabine + Etoposide + Melphalan + Rituximab | CAR.CD19-CD28-zeta-2A-iCasp9-IL15-Transduced Cord Blood NK Cells, High-Dose Chemotherapy, and Stem Cell Transplant in Treating Participants With B-cell Lymphoma | Withdrawn | USA | 0 |
NCT03589469 | Phase II | Loncastuximab tesirine | Study to Evaluate the Efficacy and Safety of Loncastuximab Tesirine in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma | Active, not recruiting | USA | 3 |
NCT03602157 | Phase I | ATLCAR.CD30.CCR4 cells Bendamustine + Fludarabine ATLCAR.CD30 cells + ATLCAR.CD30.CCR4 cells | Study of CAR-T Cells Expressing CD30 and CCR4 for r/r CD30+ HL and CTCL | Recruiting | USA | 0 |
NCT03605589 | Phase I | Blinatumomab + Pembrolizumab | Pembro + Blina Combination in Pediatric and Young Adult Patients With Relapsed/Refractory Acute Leukemia or Lymphoma | Withdrawn | USA | 0 |
NCT03625037 | Phase Ib/II | Epcoritamab | GEN3013 Trial in Patients With Relapsed, Progressive or Refractory B-Cell Lymphoma | Recruiting | USA | CAN | 13 |
NCT03645395 | Phase II | Lenalidomide + MT-3724 | PK,PD, Safety and Tolerability of Multiple Dose Regimens of MT-3724 With Lenalidomide for the Treatment of Patients With Relapsed/Refractory Diffuse Large B Cell Non-Hodgkin's Lymphoma (MT-3724_NHL_003) | Active, not recruiting | USA | 0 |
NCT03684980 | Phase I | Glucarpidase + Leucovorin + Methotrexate + Rituximab | LTA Pilot Study of Glucarpidase in Patients With Central Nervous System Lymphoma - ARM A | Recruiting | USA | 0 |
NCT03696784 | Phase I | Rimiducid Bendamustine + Fludarabine + iC9-CAR.19-IL15-Transduced CB-NK | Anti-CD19 CAR-T Cells With Inducible Caspase 9 Safety Switch for B-cell Lymphoma | Recruiting | USA | 0 |
NCT03704298 | Phase Ib/II | axicabtagene ciloleucel + Utomilumab Cyclophosphamide + Fludarabine | Safety and Efficacy of Axicabtagene Ciloleucel in Combination With Utomilumab in Adults With Refractory Large B-cell Lymphoma (ZUMA-11) | Active, not recruiting | USA | 0 |
NCT03704714 | Phase Ib/II | Cyclophosphamide + Doxorubicin + Nivolumab + Prednisone + Rituximab + Vincristine Sulfate | Nivolumab and Combination Chemotherapy in Treating Participants With Diffuse Large B-Cell Lymphoma | Recruiting | USA | 0 |
NCT03742258 | Phase I | Cyclophosphamide + Doxorubicin + Mivavotinib + Prednisone + Rituximab + Vincristine Sulfate Cyclophosphamide + Doxorubicin + Prednisone + Rituximab + Vincristine Sulfate | Combination Chemotherapy and TAK-659 as Front-Line Treatment in Treating Patients With High-Risk Diffuse Large B Cell Lymphoma | Recruiting | USA | 0 |
NCT03744676 | Phase II | Lisocabtagene maraleucel | A Safety Trial of Lisocabtagene Maraleucel (JCAR017) for Relapsed and Refractory (R/R) B-cell Non-Hodgkin Ldymphoma (NHL) in the Outpatient Setting (TRANSCEND-OUTREACH-007) | Recruiting | USA | 0 |
NCT03749018 | Phase II | Cyclophosphamide + Doxorubicin + Etoposide + Nivolumab + Prednisone + Rituximab + Vincristine Sulfate | Nivolumab With DA-REPOCH Chemotherapy Regimen in Treating Patients With Aggressive B-Cell Non-Hodgkin's Lymphoma | Recruiting | USA | 0 |
NCT03761056 | Phase II | axicabtagene ciloleucel + Cyclophosphamide + Fludarabine | Efficacy and Safety of Axicabtagene Ciloleucel as First-Line Therapy in Participants With High-Risk Large B-Cell Lymphoma (ZUMA-12) | Active, not recruiting | USA | CAN | 2 |
NCT03778073 | Phase I | Cosibelimab | Study of TG-1501 in Subjects With Relapsed or Refractory Lymphoma | Recruiting | USA | 0 |
NCT03793140 | Phase II | CPI-613 | A Study of CPI-613 for Patients With Relapsed or Refractory Burkitt Lymphoma/Leukemia or High-Grade B-Cell Lymphoma With High-Risk Translocations | Recruiting | USA | 0 |
NCT03833180 | Phase I | VLS-101 | A Phase 1 Dose-Escalation and Cohort-Expansion of VLS-101 in Hematologic Malignancies | Recruiting | USA | 0 |
NCT03920631 | Phase I | Nivolumab | Microtransplantation and Checkpoint Blockade Immunotherapy for Relapsed or Refractory B Cell Lymphomas (MicroBLITZ) | Withdrawn | USA | 0 |
NCT03922204 | Phase I | MCLA-145 | A Study of Bispecific Antibody MCLA-145 in Patients With Advanced or Metastatic Malignancies | Recruiting | USA | 1 |
NCT03934814 | Phase I | TJ011133 Pembrolizumab + TJ011133 Rituximab + TJ011133 | Study of TJ011133 Subjects With Relapsed/Refractory Advanced Solid Tumors and Lymphoma | Recruiting | USA | 1 |
NCT03990961 | Phase II | Pembrolizumab | Pembrolizumab for Patients With PD-L1 Diffuse Large B Cell Lymphoma (DLBCL) | Recruiting | USA | 0 |
NCT03995147 | Phase II | Cyclophosphamide + Doxorubicin + Pembrolizumab + Prednisone + Rituximab + Vincristine Sulfate | Pembrolizumab in Combination With Chemotherapy for Patients With Untreated B Cell Lymphoma | Recruiting | USA | 0 |
NCT04023071 | Phase I | Aldesleukin + Cyclophosphamide + Fludarabine + FT516 + Obinutuzumab Aldesleukin + Cyclophosphamide + Fludarabine + FT516 + Rituximab Aldesleukin + Cyclophosphamide + Fludarabine + FT516 | FT516 in Subjects With Advanced Hematologic Malignancies | Recruiting | USA | 0 |
NCT04045028 | Phase I | MTIG7192A Daratumumab + MTIG7192A MTIG7192A + Rituximab | A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), Pharmacodynamics (PD), and Preliminary Activity of Tiragolumab in Participants With Relapsed or Refractory Multiple Myeloma or With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma | Recruiting | USA | 1 |
NCT04074330 | Phase Ib/II | Rituximab + TAK-981 | A Study of TAK-981 in Combination With Rituximab in Participants With Relapsed/Refractory (r/r) CD20-positive (CD20+) Non-Hodgkin Lymphoma (NHL) | Recruiting | USA | CAN | 0 |
NCT04074746 | Phase I | Cyclophosphamide + Fludarabine AFM13 | Bispecific Antibody AFM13 Combined With NK Cells for Patients With Recurrent or Refractory CD30 Positive Hodgkin or Non-Hodgkin Lymphomas | Recruiting | USA | 0 |
NCT04088864 | Phase I | Anti-CD22 CAR T cells Cyclophosphamide + Fludarabine | CD22-CAR T Cells in Children and Young Adults With B Cell Malignancies | Recruiting | USA | 0 |
NCT04094311 | Phase III | Tisagenlecleucel | Study of Out of Specification for Tisagenlecleucel | Recruiting | CAN | 1 |
NCT04160195 | Phase I | Cyclophosphamide + Fludarabine Anti-CD19-CD20 CAR T cells | T Cells Expressing Fully-human Anti-CD19 and Anti-CD20 Chimeric Antigen Receptors for Treating B-cell Malignancies and Hodgkin Lymphoma | Suspended | USA | 0 |
NCT04161248 | Phase I | Cisplatin + Dexamethasone + Gemcitabine + Rituximab + Venetoclax | Phase I Master Protocol of Novel Combination Therapy for Patients With Relapsed or Refractory Aggressive B-Cell Lymphoma | Recruiting | CAN | 0 |
NCT04170283 | Phase III | Zanubrutinib | Long-term Extension Study of Zanubrutinib (BGB-3111) in Patients With B-cell Malignancies | Enrolling by invitation | USA | 5 |
NCT04205838 | Phase II | Anakinra + axicabtagene ciloleucel + Cyclophosphamide + Fludarabine | Anakinra in Preventing Severe Chimeric Antigen Receptor T-Cell Related Encephalopathy Syndrome in Patients With Recurrent or Refractory Large B-cell Lymphoma | Recruiting | USA | 0 |
NCT04210219 | Phase I | JNJ-64264681 | A Study of JNJ-64264681 in Participants With Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia | Recruiting | USA | 5 |
NCT04214886 | Phase I | CD19-CD34 CAR transduced T cells + Cyclophosphamide + Fludarabine | CD19 Chimeric Antigen Receptor (CAR) T Cells for Adults With Recurrent or Refractory B Cell Malignancies | Recruiting | USA | 0 |
NCT04220008 | Phase II | Busulfan + Clofarabine + Cyclophosphamide + Gemcitabine + Mycophenolate mofetil + Rituximab + Tacrolimus + Vorinostat Busulfan + Clofarabine + Cyclophosphamide + Gemcitabine + Mycophenolate mofetil + Tacrolimus + Vorinostat | Vorinostat and Combination Chemotherapy Before Donor Stem Cell Transplantation for the Treatment of Relapsed Aggressive B-cell or T-cell Non-Hodgkin Lymphoma | Not yet recruiting | USA | 0 |
NCT04231747 | Phase I | CC-97540 | A Study of CC-97540, CD19-targeted NEX-T Chimeric Antigen Receptor (CAR) T Cells, in Subjects With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma | Recruiting | USA | 0 |
NCT04231877 | Phase I | Cyclophosphamide + Doxorubicin + Etoposide + Filgrastim + Polatuzumab vedotin-piiq + Prednisone + Rituximab | Polatuzumab Vedotin and Combination Chemotherapy for the Treatment of Untreated Aggressive Large B-cell Lymphoma | Recruiting | USA | 0 |
NCT04245722 | Phase I | Cyclophosphamide + Fludarabine + FT596 + Obinutuzumab Cyclophosphamide + Fludarabine + FT596 Cyclophosphamide + Fludarabine + FT596 + Rituximab | FT596 as a Monotherapy and in Combination With Anti-CD20 Monoclonal Antibodies | Recruiting | USA | 0 |
NCT04257578 | Phase Ib/II | Acalabrutinib + axicabtagene ciloleucel | Acalabrutinib and Anti-CD19 CAR T-cell Therapy for the Treatment of B-cell Lymphoma | Recruiting | USA | 0 |
NCT04285268 | Phase II | Bortezomib + Rituximab + Venetoclax | Rituximab, Venetoclax, and Bortezomib for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma | Withdrawn | USA | 0 |
NCT04314843 | Phase Ib/II | axicabtagene ciloleucel + Lenzilumab Cyclophosphamide + Fludarabine | Study of Lenzilumab and Axicabtagene Ciloleucel in Participants With Relapsed or Refractory Large B-Cell Lymphoma (ZUMA-19) | Recruiting | USA | 0 |
NCT04331119 | Phase II | Duvelisib | Duvelisib Maintenance After Autologous Stem Cell Transplant in T-Cell and Indolent B-Cell Lymphomas | Recruiting | USA | 0 |
NCT04358458 | Phase Ib/II | GEN3009 | First-in-Human (FIH) Trial of GEN3009 in Subjects With Relapsed or Refractory B-Cell Non-Hodgkin Lymphomas | Recruiting | USA | 6 |
NCT04384484 | Phase III | Loncastuximab tesirine + Rituximab Gemcitabine + Oxaliplatin + Rituximab | Study to Evaluate Loncastuximab Tesirine With Rituximab Versus Immunochemotherapy in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (LOTIS 5) | Recruiting | USA | 2 |
NCT04442022 | Phase II | Cisplatin + Dexamethasone + Gemcitabine + Rituximab Cisplatin + Dexamethasone + Gemcitabine + Rituximab + Selinexor | A Study of Rituximab-Gemcitabine-Dexamethasone-Platinum (R-GDP) With or Without Selinexor in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma | Recruiting | USA | 9 |
NCT04464798 | Phase I | Iberdomide Iberdomide + Obinutuzumab Iberdomide + Rituximab | A Dose Finding and Safety Study of CC-220, Alone and in Combination With an Anti-CD20 Monoclonal Antibody (mAb) in Subjects With Relapsed or Refractory Lymphomas | Not yet recruiting | USA | 3 |
NCT04502706 | Phase I | FSI-189 FSI-189 + Rituximab | Study of FSI-189 as Monotherapy and in Combination With Rituximab in Participants With Relapsed/Refractory Non-Hodgkin Lymphoma | Recruiting | USA | 0 |
NCT04509700 | Phase II | Parsaclisib Itacitinib + Parsaclisib | Rollover Study to Provide Continued Treatment for Participants With B-Cell Malignancies Previously Enrolled in Studies of Parsaclisib (INCB050465) | Recruiting | USA | 1 |
NCT04535102 | Phase II | Bendamustine + Polatuzumab vedotin-piiq + Rituximab | POLA+BR for Relapsed or Refractory DLBCL | Recruiting | USA | 0 |
NCT04540796 | Phase I | JNJ-75348780 | A Study of JNJ-75348780 in Participants With Non-Hodgkin Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL) | Recruiting | USA | 7 |
NCT04548648 | Phase II | Acalabrutinib Isavuconazole | LCCC1841: A Phase 2 Trial of Acalabrutinib in Relapsed/Refractory Primary and Secondary CNS Lymphomas | Not yet recruiting | USA | 0 |
NCT04555811 | Phase I | FT596 + Rituximab | FT596 With Rituximab as Relapse Prevention After Autologous HSCT for NHL | Recruiting | USA | 0 |
NCT04572763 | Phase Ib/II | Copanlisib + Venetoclax | Copanlisib Plus Venetoclax in R/R DLBCL | Not yet recruiting | USA | 0 |
NCT04594642 | Phase I | TNB-486 | A Study of TNB-486 in Subjects With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma | Recruiting | USA | 1 |
NCT04599634 | Phase I | Hu5F9-G4 + Obinutuzumab + Venetoclax | Venetoclax With Obinutuzumab and Magrolimab (VENOM) in Relapsed and Refractory Indolent B-cell Malignancies | Not yet recruiting | USA | 0 |
NCT04608487 | Phase I | Cyclophosphamide + Fludarabine axicabtagene ciloleucel | Axi-cel in CNS Lymphoma | Recruiting | USA | 0 |
NCT04657224 | Phase I | JNJ-64264681 + JNJ-67856633 | A Study of JNJ-64264681 and JNJ-67856633 in Participants With Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia | Recruiting | USA | 11 |
NCT04665765 | Phase II | Polatuzumab vedotin-piiq Carboplatin + Etoposide + Ifosfamide + Polatuzumab vedotin-piiq + Rituximab | Polatuzumab Vedotin, Rituximab, Ifosfamide, Carboplatin, and Etoposide (PolaR-ICE) as Initial Salvage Therapy for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma | Recruiting | USA | 0 |
NCT04739813 | Phase I | Ibrutinib + Lenalidomide + Obinutuzumab + Polatuzumab vedotin-piiq + Prednisone + Venetoclax | Phase 1 Study of Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid in Combination With Polatuzumab (ViPOR-P) in Relapsed/Refractory B-cell Lymphoma | Not yet recruiting | USA | 0 |
NCT04830137 | Phase I | NX-2127 | A Study of NX-2127 in Adults With Relapsed/Refractory B-cell Malignancies | Recruiting | USA | 0 |